Pheochromocytoma and paraganglioma market to grow 7.3% CAGR by 2036 with new targeted therapies advancing.

The pheochromocytoma and paraganglioma (PCPG) market is projected to grow at a 7.3% CAGR through 2036, driven by new drug classes like SSTR2 analogs, dopamine receptor D2 agonists, and novel radioligand therapies. Advances in radiopharmaceuticals such as 131I-MIBG and 177Lu-DOTATATE are expanding treatment options beyond surgery and chemotherapy, especially for advanced cases. Key companies including Novartis, Jazz Pharmaceuticals, and Perspective Therapeutics are developing innovative therapies expected to reshape the market. Rising incidence, improved diagnosis, and emerging precision treatments signal a shift toward more effective, mechanism-based care for this rare cancer type.